Online inquiry

IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9091MR)

This product GTTS-WQ9091MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&PMEL gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_001200053.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6490
UniProt ID P07766; P40967
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9091MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12658MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ5143MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ748MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ14219MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ5526MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ4184MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ7914MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ3337MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW